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Observational studies support an association between a low blood 25-hydroxyvitamin
D level and the risk of type 2 diabetes. However, whether vitamin D supplementation
lowers the risk of diabetes is unknown.
METHODS

We randomly assigned adults who met at least two of three glycemic criteria for prediabetes (fasting plasma glucose level, 100 to 125 mg per deciliter; plasma glucose
level 2 hours after a 75-g oral glucose load, 140 to 199 mg per deciliter; and glycated
hemoglobin level, 5.7 to 6.4%) and no diagnostic criteria for diabetes to receive 4000 IU
per day of vitamin D3 or placebo, regardless of the baseline serum 25-hydroxyvitamin
D level. The primary outcome in this time-to-event analysis was new-onset diabetes,
and the trial design was event-driven, with a target number of diabetes events of 508.
RESULTS

A total of 2423 participants underwent randomization (1211 to the vitamin D group and
1212 to the placebo group). By month 24, the mean serum 25-hydroxyvitamin D level in
the vitamin D group was 54.3 ng per milliliter (from 27.7 ng per milliliter at baseline),
as compared with 28.8 ng per milliliter in the placebo group (from 28.2 ng per milliliter
at baseline). After a median follow-up of 2.5 years, the primary outcome of diabetes occurred in 293 participants in the vitamin D group and 323 in the placebo group (9.39
and 10.66 events per 100 person-years, respectively). The hazard ratio for vitamin D as
compared with placebo was 0.88 (95% confidence interval, 0.75 to 1.04; P = 0.12). The
incidence of adverse events did not differ significantly between the two groups.
CONCLUSIONS

Among persons at high risk for type 2 diabetes not selected for vitamin D insufficiency, vitamin D3 supplementation at a dose of 4000 IU per day did not result in a
significantly lower risk of diabetes than placebo. (Funded by the National Institute of
Diabetes and Digestive and Kidney Diseases and others; D2d ClinicalTrials.gov number,
NCT01942694.)
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M

ore than 84 million adults in
the United States have an increased risk
of type 2 diabetes, based on a fasting
glucose or glycated hemoglobin level above the
normal range but below the threshold for diabetes.1 Persons at high risk for type 2 diabetes who
are overweight or obese and who have elevated
fasting glucose levels and glucose intolerance
(according to a 75-g oral glucose-tolerance test)
can slow progression to diabetes with lifestyle
changes.2 However, achieving and maintaining
sufficient lifestyle change is challenging, and the
residual risk of diabetes remains elevated, even
after successful weight loss.
Over the past decade, a low blood 25-hydroxy
vitamin D level has emerged as a possible risk
factor for type 2 diabetes, and vitamin D supplementation has been proposed as a potential intervention to lower diabetes risk.3,4 The hypothe
sis that vitamin D status may influence the risk
of type 2 diabetes is biologically plausible, because both impaired pancreatic beta-cell function and insulin resistance have been reported
with low blood 25-hydroxyvitamin D levels.5 Observational studies support an association between a low blood 25-hydroxyvitamin D level and
the risk of diabetes.6 In short-term mechanistic
studies, vitamin D supplementation improved
the disposition index, a measure of pancreatic
beta-cell function, by 40%.7 However, whether
vitamin D supplementation lowers the risk of
diabetes is unclear.8-10 The Vitamin D and Type 2
Diabetes (D2d) trial was conducted to test
whether vitamin D supplementation reduces the
risk of type 2 diabetes among adults at high risk
for the disorder.

Me thods
Trial Design

This randomized, double-blind, placebo-controlled
clinical trial evaluated the safety and efficacy of
oral administration of vitamin D3 (cholecalciferol;
4000 IU per day) for diabetes prevention in
adults at high risk for type 2 diabetes.11 The
trial protocol (available with the full text of this
article at NEJM.org) was designed by the planning committee and the primary sponsor (National Institute of Diabetes and Digestive and
Kidney Diseases) without input from manufacturers11 and involved collaboration among 22
academic medical centers in the United States
(https://d2dstudy.org/sites). A sponsor-appointed
n engl j med 381;6

data and safety monitoring board approved the
protocol and provided independent monitoring
of the trial. The institutional review board at
each clinical site also approved the protocol, and
all the participants provided written informed
consent. The data were collected by trial-site
personnel and stored in an electronic data-capture database. The statistical team at the coordinating center analyzed the data and vouches for
its accuracy. All the authors vouch for the accuracy and completeness of the data and for the
fidelity of the trial to the protocol. They also
contributed to the interpretation of the results
and the preparation, review, and approval of the
manuscript and made the decision to submit the
manuscript for publication.
No pharmaceutical manufacturers contributed
to the planning, design, or conduct of the trial.
Trial pills were purchased from an independent
nutritional-supplement manufacturing company
that has no association with any members of the
D2d Research Group.
Participants

Participants met at least two of three glycemic
criteria for prediabetes as defined by the 2010
American Diabetes Association (ADA) guidelines:
fasting plasma glucose level, 100 to 125 mg per
deciliter (5.6 to 6.9 mmol per liter); plasma glucose level 2 hours after a 75-g oral glucose load,
140 to 199 mg per deciliter (7.8 to 11.0 mmol per
liter); and glycated hemoglobin level, 5.7 to 6.4%
(39 to 47 mmol per mole).12 Other inclusion criteria were an age of 30 years or older (25 years
or older for American Indians, Alaska Natives,
or Native Hawaiians or other Pacific Islanders)
and a body-mass index (BMI, the weight in kilograms divided by the square of the height in
meters) of 24 to 42 (22.5 to 42 for Asian Americans). A low serum 25-hydroxyvitamin D level
was not an inclusion criterion.
Key exclusion criteria were any glycemic criterion in the diabetes range,12 factors (other than
hyperglycemia and race) affecting the glycated
hemoglobin level, use of diabetes or weight-loss
medications, or use of supplements containing
vitamin D at a dose of more than 1000 IU per
day or calcium at a dose of more than 600 mg
per day. For a complete list of eligibility criteria,
see the Supplementary Appendix (available at
NEJM.org). The recruitment process relied primarily on electronic-health-record identification
of potentially eligible adults who were then
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screened in person and, if qualified, had a second screening visit to determine final eligibility
according to measured fasting plasma glucose,
2-hour post-load plasma glucose, and glycated
hemoglobin at the central laboratory of the trial.13
Intervention and Procedures

Participants were randomly assigned to take a
single, once-daily soft-gel pill containing either
4000 IU of vitamin D3 or matching placebo.
Randomization was block-stratified according
to trial site, BMI (<30 or ≥30), and race (white
or nonwhite). Participants received a bottle of
trial pills at the time of randomization and every
6 months thereafter. Bottles with unused pills
were returned at each visit to estimate adherence.
To maximize the ability of the trial to observe
a treatment effect, participants were asked to
refrain from using diabetes-specific or weightloss medications during the trial and to limit the
use of outside-of-trial vitamin D to 1000 IU per
day from all supplements, including multivitamins. Because of concern that high intake of
calcium from supplements may be associated
with adverse outcomes, participants were asked
to limit calcium supplements to 600 mg per day.
During the trial, participants were provided with
information on diabetes prevention through information sheets and twice-yearly group meetings.
Follow-up visits occurred at month 3, month 6,
and twice per year thereafter. Midway between
the in-person visits, an interim contact (telephone or email) took place. All visits and contacts were designed to promote retention, encourage adherence to the trial regimen, and assess
for diabetes, occurrence of adverse events, and
use of high-dose vitamin D supplements, diabetes medications, and weight-loss medications.

of
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old, confirmatory testing was performed for the
positive measure within 8 weeks. If only the
measure for 2-hour post-load plasma glucose
met the threshold, then a 75-g oral glucose-tolerance test to reassess all three glycemic measures
was repeated. If the repeat measure was positive
or both fasting plasma glucose and glycated
hemoglobin were positive (in the case of a repeat
oral glucose-tolerance test), then the participant
was considered to have met the diabetes outcome. A diagnosis of diabetes that was made
outside the trial was validated by in-trial laboratory testing or adjudicated by an independent
clinical-outcomes committee.
During the trial, research staff, caregivers,
and participants were unaware of glycemic test
results until a participant met the diabetes outcome. Safety was assessed by means of participant report and annual fasting measurements of
serum calcium, serum creatinine, and morning
spot urine calcium:creatinine ratio (a rough estimate of urine calcium excretion).14
Laboratory Testing

Serum calcium and creatinine were analyzed locally at each site, and the estimated glomerular
filtration rate was calculated.15 Other blood and
urine specimens were processed locally and
shipped to the central laboratory. Glycated
hemoglobin was measured with the use of an
ion-exchange high-performance liquid chromatography method certified by the National Glycohemoglobin Standardization Program.16 Plasma
glucose was measured with the use of a hexokinase method. Stored serum samples from the
baseline, month 12, and month 24 visits were
used to measure 25-hydroxyvitamin D by liquid
chromatography–tandem mass spectrometry validated by a quarterly proficiency-testing program
Outcomes
administered by the Vitamin D External Quality
The primary outcome in this time-to-event analy- Assessment Scheme.17,18
sis was new-onset diabetes, based on annual
glycemic testing of fasting plasma glucose, gly- Statistical Analysis
cated hemoglobin, and 2-hour post-load plasma The trial was designed as an event-driven trial
glucose and semiannual testing of fasting plas- with a target of 508 diabetes events and a total
ma glucose and glycated hemoglobin. If two or sample size of 2382 participants assigned equalthree of the glycemic measures met the 2010 ly to the vitamin D group and placebo group, on
ADA thresholds for diabetes,12 the participant the basis of a hypothesized hazard ratio of 0.75
was considered to have met the diabetes out- in the vitamin D group, an incidence of diabetes
come. When only the measure for fasting plasma of 10% per year in the placebo group, a type I
glucose or glycated hemoglobin met the thresh- error rate of 0.0501 (with a single interim analy-
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sis taken into account), a power of 90%, a recruitment period of 2 years, a trial duration of
4 years, and a withdrawal rate of 5% per year
of follow-up.19
Intention-to-treat analyses compared groups
defined by the randomization procedure and included all participants irrespective of adherence
to the assigned intervention or to the protocol
(e.g., use of diabetes or weight-loss medications).
Follow-up time for all analyses was calculated as
the time from randomization until the occurrence of the primary outcome, death, withdrawal,
or last follow-up encounter free from diabetes.
No imputation was performed for missing data,
but we conducted a sensitivity analysis to assess
for noninformative censoring of incomplete data
(see the Supplementary Appendix).
Because the use of a diabetes-specific medication would be considered a “competing event”
for the primary outcome, we prespecified a sensitivity analysis in which the primary outcome
was the time to new-onset diabetes according to
trial criteria or use of a diabetes-specific medication. As planned in the protocol, we conducted an
exploratory per-protocol analysis that censored
follow-up data when a participant stopped the
trial pills, started a diabetes or weight-loss medication, or took out-of-trial vitamin D from supplements above the trial limit of 1000 IU per day.
The protocol specified that this event-driven
trial would continue until the required number
of diabetes events (508) was reached. A prespecified interim analysis for the data and safety
monitoring board to examine harm or superior
efficacy with the use of a Haybittle–Peto boundary20 was conducted when approximately 70% of
the required events (364 of 508) had accrued,
and the data and safety monitoring board recommended that the trial proceed to its planned
conclusion. Because the efficiency of event-driven
trials is increased by stopping when the required
number of events is achieved,21 we conducted
blinded monitoring of event count and specified that when the trial was within approximately
2 months of reaching 508 events, the subsequent
scheduled follow-up visit for each participant
would be considered the last visit. All events that
occurred during the trial, including those that occurred after the target of 508 events was reached,
were used to generate the primary results.
Kaplan–Meier estimates were plotted for each

n engl j med 381;6

group. Cox proportional-hazards models were
used to calculate the hazard ratio for new-onset
diabetes between the two groups.22 The model
included group assignment as its main predictor
variable and the stratification variables (trial site,
BMI, and race). We also show a model without
the stratification variables. Comparisons between
the two groups at baseline and with respect to the
rate of withdrawal, discontinuation of trial pills,
use of diabetes or weight-loss medications, and
supplemental intake above the trial limit used
Fisher’s exact test, the chi-square test, the Wilcoxon rank-sum test, or the pooled-variance
t‑test.
Variability of response to vitamin D supplementation was assessed in prespecified subgroups
defined by key baseline variables. Rates of adverse events were compared between the two
groups. When evaluating the significance of the
prespecified subgroup analyses, we used the
Hochberg sequential procedure to adjust for multiple comparisons, if necessary. No adjustments
were made for the safety analyses or the planned
exploratory or post hoc analyses for the primary
outcome; therefore, only point estimates and
95% confidence intervals are presented without
P values.

R e sult s
Participants

From October 2013 through February 2017, a total of 7133 persons were screened (Fig. 1), and
2423 were randomly assigned to receive vitamin D
(1211 participants) or placebo (1212 participants);
these participants were included in the intentionto-treat population (Table 1, and Table S1 in the
Supplementary Appendix). A total of 44.8% of
the participants were women, 33.3% were of nonwhite race, and 9.3% were of Hispanic ethnic
background.24 The participants had a mean age
of 60.0 years, a mean BMI of 32.1, and a mean
glycated hemoglobin level of 5.9% (48 mmol per
mole). A total of 84.2% of the participants met
the glycemic criteria for both fasting plasma
glucose and glycated hemoglobin; approximately
one third met all three glycemic criteria.
The last trial encounter was in November 2018.
In the two groups, the median follow-up was 2.5
years (interquartile range, 1.9 to 3.5 [vitamin D]
and 1.7 to 3.5 [placebo]). Before reaching a pri-
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4710 Did not meet eligibility criteria
3850 Did not meet glycemic
criteria
106 Used supplements containing vitamin D at dose of
>1000 IU/day or calcium
at dose of >600 mg/day
159 Had abnormal laboratory
result
223 Withdrew consent or were
not interested
372 Had other reason

2423 Underwent randomization

1212 Were assigned to receive
placebo daily
1211 Received placebo

3 Had no contact after randomization
5 Died
34 Withdrew
1 Was withdrawn administratively
137 Discontinued trial pills
27 Had protocol-specified adverse
event
20 Had other adverse event
86 Chose to discontinue
4 Had other reason

5 Had no contact after randomization
5 Died
28 Withdrew
108 Discontinued trial pills
24 Had protocol-specified adverse
event
13 Had other adverse event
66 Chose to discontinue
5 Had other reason

1201 Completed ≥1 follow-up
encounter

1199 Completed ≥1 follow-up
encounter

1131 Met primary outcome, died, or
completed last follow-up encounter

1130 Met primary outcome, died, or
completed last follow-up encounter

1211 Were included in the intentionto-treat analysis

1212 Were included in the intentionto-treat analysis

Primary Outcome

Figure 1. Screening, Randomization, and Follow-up.
One participant in the vitamin D group was withdrawn administratively after
a clinical site closed down early in the trial. Protocol-specified adverse events
that led to discontinuation of the trial pills were hypercalcemia, a fasting
urine calcium:creatinine ratio of more than 0.375, a low estimated glomerular
filtration rate, and nephrolithiasis. Of the 2423 participants who underwent
randomization, 14 (9 in the vitamin D group and 5 in the placebo group)
were subsequently found not to meet all eligibility criteria.
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mary outcome event, 10 participants (5 in each
group) died, and 62 (34 in the vitamin D group
and 28 in the placebo group) withdrew consent
(Fig. 1). In total, 99.1% of the cohort (1201 participants in the vitamin D group and 1199 in
the placebo group) contributed follow-up data,
through either a visit that included central-laboratory testing or a nonvisit encounter to capture
a diagnosis of diabetes outside the trial.
The mean baseline level of serum 25-hydroxy
vitamin D was 28.0 ng per milliliter (69.9 nmol
per liter), with no significant difference between
the two groups; 78.3% of the participants had a
level equal to or greater than 20 ng per milliliter
(50 nmol per liter) (Table 1). The mean 25-hydroxy
vitamin D levels in the vitamin D group at
month 12 (52.3 ng per milliliter [130.5 nmol
per liter]) and month 24 (54.3 ng per milliliter
[135.5 nmol per liter]) were higher than those
in the placebo group (28.1 ng per milliliter
[70.1 nmol per liter] and 28.8 ng per milliliter
[71.9 nmol per liter], respectively) (Fig. S1 in the
Supplementary Appendix).

7133 Persons were assessed for eligibility

1211 Were assigned to receive
4000 IU of vitamin D daily
1211 Received vitamin D

of

By the end of the trial, diabetes had developed
in 616 patients. New-onset diabetes (the primary
outcome) occurred in 293 participants (273 cases
diagnosed by trial-specific laboratory testing and
20 diagnosed by adjudication) in the vitamin D
group and 323 patients (305 cases diagnosed by
trial-specific laboratory testing and 18 diagnosed
by adjudication) in the placebo group (9.39 events
and 10.66 events per 100 person-years, respectively). The hazard ratio in the vitamin D group
was 0.88 (95% confidence interval [CI], 0.75 to
1.04; P = 0.12) (Fig. 2). When the stratification
variables were not included in the model, the
hazard ratio in the vitamin D group was 0.87
(95% CI, 0.75 to 1.02). In a sensitivity analysis to
account for missing data, the hazard ratio did
not change substantially (see the Supplementary
Appendix).
In the sensitivity analysis in which diabetes
was defined as new-onset diabetes according to
trial criteria or the use of a diabetes-specific
medication, the hazard ratio in the vitamin D
group was 0.88 (95% CI, 0.75 to 1.02). The results of the subgroup analyses were consistent
with the findings of the main analysis; there
was no apparent heterogeneity of treatment effect across the prespecified subgroups (Fig. 3).

nejm.org

August 8, 2019

Vitamin D and Prevention of Diabetes

Table 1. Baseline Characteristics of the Participants.*
Characteristic

Overall
(N = 2423)

Vitamin D
(N = 1211)

Placebo
(N = 1212)

60.0±9.9

59.6±9.9

60.4±10.0

1086 (44.8)

541 (44.7)

545 (45.0)

Demographic
Age — yr
Female sex — no. (%)
Race — no. (%)†
Asian

130 (5.4)

66 (5.5)

64 (5.3)

Black

616 (25.4)

301 (24.9)

315 (26.0)

White

1616 (66.7)

810 (66.9)

806 (66.5)

Other

61 (2.5)

34 (2.8)

27 (2.2)

Hispanic or Latino ethnic group — no. (%)†

225 (9.3)

120 (9.9)

105 (8.7)

Body-mass index

32.1±4.5

32.0±4.5

32.1±4.4

Fasting plasma glucose — mg/dl

107.9±7.4

108.0±7.4

107.8±7.4

2-Hr post-load plasma glucose — mg/dl

137.2±34.3

136.9±34.3

137.6±34.3

5.9±0.2

5.9±0.2

5.9±0.2

28.0±10.2

27.7±10.2

28.2±10.1

Laboratory assessments

Glycated hemoglobin — %
Serum 25-hydroxyvitamin D
Mean — ng/ml
Distribution — no./total no. (%)‡
<12 ng/ml

103/2422 (4.3)

60/1211 (5.0)

43/1211 (3.6)

12–19 ng/ml

422/2422 (17.4)

216/1211 (17.8)

206/1211 (17.0)

876/2422 (36.2)

453/1211 (37.4)

423/1211 (34.9)

1021/2422 (42.2)

482/1211 (39.8)

539/1211 (44.5)

20–29 ng/ml
≥30 ng/ml

*	Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. To convert the values for glu‑
cose to millimoles per liter, multiply by 0.05551. To convert the values for 25-hydroxyvitamin D to nanomoles per liter,
multiply by 2.496.
†	Race and ethnic group were reported by the participant. The category “other” includes American Indian or Alaska
Native; Native Hawaiian or other Pacific Islander; and other race. Ethnic group includes any race.
‡	Categories of serum 25-hydroxyvitamin D are based on the 2010 Dietary Reference Intakes for calcium and vitamin D
recommended by the Food and Nutrition Board of the Institute of Medicine.23

In a post hoc analysis of data from participants
with a baseline 25-hydroxyvitamin D level of less
than 12 ng per milliliter (30 nmol per liter) (103
participants), the hazard ratio in the vitamin D
group was 0.38 (95% CI, 0.18 to 0.80). Among
those with a baseline 25-hydroxyvitamin D level
equal to or greater than 12 ng per milliliter
(2319 participants), the hazard ratio in the vitamin D group was 0.92 (95% CI, 0.78 to 1.08).
Adherence

A total of 170 participants (14.0%) in the vitamin D group and 172 (14.2%) in the placebo
group stopped trial pills, took diabetes or weightloss medications, or took outside-of-trial vitan engl j med 381;6

min D supplements above the trial limit before
the diagnosis of diabetes. During the trial, more
participants in the placebo group than in the
vitamin D group started diabetes or weight-loss
medications (Fig. S2 in the Supplementary Appendix). Although overall adherence to the trial
regimen was high (85.8% of prescribed pills
were taken), more participants in the vitamin D
group (11.3%) than in the placebo group (8.9%)
stopped trial pills (difference, 2.4 percentage
points; 95% CI, 0.0 to 4.8) (Fig. S3 in the Supplementary Appendix). During follow-up, more
participants in the placebo group (5.2%) than in
the vitamin D group (2.6%) reported use of
outside-of-trial vitamin D supplements above the
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Probability of Diabetes-free Survival

0.9
0.8
Vitamin D
Placebo

Discussion

0.6
0.5
0.4
0.3
0.2
Hazard ratio for diabetes, 0.88 (95% CI, 0.75–1.04)
P=0.12

0.1
0.0

0

6

12

18

24

30

36

42

48

54

283
258

141
121

21
13

Months since Randomization
No. at Risk
Vitamin D
Placebo

1211
1212

1171
1171

1089
1091

1001
975

812
779

625
577

466
419

Figure 2. Kaplan–Meier Curves for Survival Free from Diabetes among Adults
at Risk for Type 2 Diabetes.
The hazard ratio for new-onset diabetes between the vitamin D group and
the placebo group is derived from Cox regression, with stratification accord‑
ing to trial site, body-mass index, and race.

trial limit of 1000 IU per day (difference, 2.6
percentage points; 95% CI, 1.1 to 4.2) (Fig. S2 in
the Supplementary Appendix). There was no significant difference between the two groups in the
use of outside-of-trial calcium supplements above
the trial limit.
In the exploratory per-protocol analysis that
censored follow-up data when a participant started a diabetes or weight-loss medication, stopped
the trial pills, or took out-of-trial vitamin D from
supplements above the trial limit of 1000 IU per
day, the primary outcome occurred in 265 participants (21.9%) in the vitamin D group and
304 (25.1%) in the placebo group (hazard ratio,
0.84; 95% CI, 0.71 to 1.00).
Safety

There were no significant between-group differences in the protocol-specified adverse
events of interest: hypercalcemia, a fasting urine
calcium:creatinine ratio of more than 0.375, a
low estimated glomerular filtration rate, and
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nephrolithiasis (Table 2). Overall, 47 participants
(3.9%) in the vitamin D group stopped the trial
pills because of an adverse event, as compared
with 37 (3.1%) in the placebo group (difference,
0.8 percentage points; 95% CI, −0.7 to 2.3).

1.0

0.7

of

n engl j med 381;6

In this multicenter, randomized, placebo-controlled trial involving persons at high risk for
type 2 diabetes not selected for vitamin D insufficiency, vitamin D3 supplementation at a dose of
4000 IU per day did not result in a significantly
lower risk of diabetes than placebo after a median follow-up of 2.5 years.
While our trial was being conducted, two
other trials that were designed to test whether
vitamin D supplementation lowers the risk of
type 2 diabetes among persons at risk showed
hazard ratios with vitamin D that were similar
to those in our trial.25,26 In the Tromsø Vitamin D
and T2DM Trial (Norway), which randomly assigned 511 white adults with prediabetes to
20,000 IU per week (approximately 2900 IU per
day) of vitamin D3 or placebo, the risk of diabetes was numerically lower in the vitamin D group
than in the placebo group, but the difference
was not significant (hazard ratio, 0.90; 95% CI,
0.69 to 1.18).25 In the Diabetes Prevention with
Active Vitamin D study (Japan), which randomly
assigned 1256 adults with prediabetes to an active form of vitamin D analogue (eldecalcitol)
or placebo, the risk of diabetes was also lower
in the vitamin D group than in the placebo
group, but the difference was again not significant (hazard ratio, 0.87; 95% CI, 0.68 to 1.09).27
We powered our trial to detect a 25% lower risk
of diabetes with vitamin D than with placebo.
On the basis of the results from all three trials,
vitamin D supplementation may decrease diabetes risk among persons at risk for diabetes not
selected for vitamin D insufficiency by a smaller
effect size (10 to 15%), but none of these trials
were powered to test this effect size.
Our trial has several strengths. We used contemporary glycemic criteria to assemble a diverse
cohort at high risk for diabetes with a hyperglycemic pattern closely matching how prediabetes
is diagnosed in clinical practice, most commonly
with fasting plasma glucose and glycated hemoglobin. The vitamin D dose of 4000 IU per day
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Subgroup

Vitamin D

Placebo

Hazard Ratio for Diabetes
(95% CI)

no. of events/no. of participants
Serum 25-hydroxyvitamin D
<20 ng/ml
≥20 ng/ml
Race
White
Black
Other
Glycemic criteria for prediabetes
Met all three criteria
Met two criteria
Body–mass index
<30
≥30
Impaired glucose tolerance
Yes
No
Ethnic group
Hispanic
Non–Hispanic
Sex
Female
Male
Waist circumference
<Median of 104.2 cm
≥Median of 104.2 cm
Age
<Median of 60.9 yr
≥Median of 60.9 yr
Geographic location
At or above 37° north latitude
Below 37° north latitude
Calcium intake from supplements
No intake
Any intake

73/276
220/935

66/249
256/962

0.87 (0.61–1.22)
0.89 (0.74–1.06)

207/810
64/301
22/100

227/806
69/315
27/91

0.90 (0.75–1.09)
0.83 (0.58–1.18)
0.86 (0.48–1.56)

143/427
150/784

163/429
160/783

0.86 (0.68–1.09)
0.90 (0.72–1.13)

82/435
211/776

105/429
218/783

0.71 (0.53–0.95)
0.97 (0.80–1.17)

191/604
102/607

215/635
108/577

0.92 (0.75–1.12)
0.86 (0.65–1.13)

36/120
257/1091

27/105
296/1107

1.14 (0.68–1.92)
0.86 (0.72–1.02)

131/541
162/670

127/545
196/667

0.98 (0.77–1.26)
0.82 (0.66–1.01)

127/620
166/591

135/585
188/627

0.82 (0.64–1.05)
0.95 (0.76–1.17)

158/622
135/589

153/587
170/625

0.97 (0.77–1.21)
0.80 (0.64–1.01)

205/892
88/319

235/898
88/314

0.85 (0.70–1.03)
0.97 (0.72–1.32)

198/826
95/385

216/793
107/419

0.81 (0.66–0.98)
1.05 (0.79–1.40)
0.50

0.75

Vitamin D Better

1.00

1.25

1.50

Placebo Better

Figure 3. Prespecified Subgroup Analyses.
Participants met at least two of three glycemic criteria for prediabetes: fasting plasma glucose level, 100 to 125 mg per deciliter (5.6 to
6.9 mmol per liter); plasma glucose level 2 hours after a 75-g oral glucose load, 140 to 199 mg per deciliter (7.8 to 11.0 mmol per liter)
(impaired glucose tolerance); and glycated hemoglobin level, 5.7 to 6.4% (39 to 47 mmol per mole). To convert the values for 25-hydroxy
vitamin D to nanomoles per liter, multiply by 2.496.

was selected to balance safety and efficacy and
resulted in a large difference in the serum
25-hydroxyvitamin D level between the trial
groups in the first 2 years of follow-up. In 94%
of cases, the primary outcome was ascertained
by trial-specific laboratory testing based on current ADA criteria and required two tests in the
diabetes range for diagnosis. Our cohort was
recruited at a constant rate throughout the cal-
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endar year, which reduced the potential of confounding by seasonal variability. Finally, the observed rate of new-onset diabetes in the placebo
group (10.7 events per 100 person-years) was
consistent with our estimate of 10 events per 100
person-years.
Overall adherence was high, and overall use
of off-protocol concomitant therapies was low.
However, among nonadherent participants, more
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*	Hypercalcemia was defined as a serum calcium level (uncorrected for albumin level) higher than the upper limit of the normal range for the clinical laboratory at each clinical site. The
fasting morning urine calcium:creatinine ratio was measured by the central laboratory. A low estimated glomerular filtration rate was defined as a rate equal to or lower than 30 ml per
minute per 1.73 m2 of body-surface area based on serum creatinine measured at the clinical laboratory at each clinical site.

0.97 (0.28–3.35)
0.17
5
0.16
5
Death

1.16 (0.65–2.07)

0.48 (0.04–5.36)

1.00 (0.83–1.20)
153
7.52
228
173
235
Serious adverse event

7.53

20

2
0.07

0.69
21

2
1

24
0.80

0.03
1
Low estimated glomerular filtration rate

25

1

n e w e ng l a n d j o u r na l

Nephrolithiasis, participant-reported

0.97 (0.06–15.52)

1.62 (0.39–6.77)
3

1
0.03

0.10
3

1
1

5

Fasting urine calcium:creatinine ratio >0.375

Within-trial laboratory evaluation*

Hypercalcemia

0.16

5

37
no.
no./100 person-yr

0.03

1.23 (0.80–1.90)
no.
1.22

no./100 person-yr

Participants
with ≥1 Event
Event
Rate
Participants
with ≥1 Event
Event
Rate

1.51
47
Any adverse event leading to discontinuation of
the trial pills

Event

Table 2. Protocol-Specified Adverse Events.

No. of
Events

Vitamin D (N = 1211)

No. of
Events

Placebo (N = 1212)

Incidence Rate Ratio for
Vitamin D vs. Placebo
(95% CI)

The

n engl j med 381;6

of

m e dic i n e

in the placebo group started diabetes or weightloss medications and took outside-of-trial vitamin D supplements above the trial limit, whereas
more in the vitamin D group stopped the trial
pills for any reason. Whether these differences
among nonadherent participants shifted the risk
difference between the two groups toward or
away from null in the intention-to-treat or perprotocol analysis is unknown.
Response to a nutritional intervention depends on nutritional status at baseline; thus, if
vitamin D has an effect on diabetes prevention,
persons with a higher baseline level of serum
25-hydroxy
vitamin D would be expected to
have less effect from supplementation than those
with a lower baseline level.28 Owing to ethical
and practical considerations, a lack of consensus on the preferred 25-hydroxyvitamin D level,
and our desire to maximize the external validity of the trial, we specifically did not include
serum 25-hydroxyvitamin D as an eligibility
criterion. Because vitamin D supplements are
used increasingly in the U.S. adult population,29 approximately 8 of 10 participants had a
baseline serum 25-hydroxyvitamin D level that
was considered to be sufficient according to
current recommendations (≥20 ng per milliliter)
to reduce the risk of many outcomes,23,30 including diabetes.6 The high percentage of participants with adequate levels of vitamin D may
have limited the ability of the trial to detect a
significant effect.
The vitamin D dose of 4000 IU per day is the
recommended upper intake level to avert potential toxicity,23 although data from large trials on
the safety on this dose have been scant. There is
concern that 25-hydroxyvitamin D levels above
50 ng per milliliter (125 nmol per liter) may be
associated with adverse effects.23,30 In our trial,
vitamin D3 supplementation at a dose of 4000 IU
per day resulted in no significant differences between the two groups in the protocol-specified
adverse events of interest (hypercalcemia, a fasting
urine calcium:creatinine ratio of >0.375, a low
estimated glomerular filtration rate, and nephrolithiasis). The 24-hour urine calcium level was not
measured.31
In conclusion, among persons at high risk for
type 2 diabetes not selected for vitamin D insufficiency, vitamin D3 supplementation at a dose of
4000 IU per day did not result in a significantly
lower risk of diabetes than placebo.
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